3 Keys to This Surging Biotech's Star-Studded Year
Biotech is a sector that can make investors rich like no other, and even the biggest players in the business aren't afraid of jumping out to big gains. Take Gilead Sciences , one of biotech's top names that has seen its stock roar to gains of more than 87% year-to-date.
Gilead has long dominated the HIV treatment space, but the company's made big moves this year to set it and its investors up for a great future. From the sturdy rise of new HIV compound Stribild to the approval of a new oral hepatitis-C regimen, Gilead hasn't stopped to slow down ever since January kicked off.
But can Gilead's moves this year make you rich for the long term? In the video below, Fool contributor Dan Carroll takes you through three of Gilead's biggest drivers behind its great year -- and what these mean for the stock's long-term potential.
1 market opportunity that's blown away the experts
Gilead has been a big winner in 2013, but can you unearth the next stock set to explode for huge gains? Opportunities to get wealthy from a single investment don't come around often, but they do exist, and our chief technology officer believes he's found one. In this free report, Jeremy Phillips shares the single company that he believes could transform not only your portfolio, but your entire life. To learn the identity of this stock for free and see why Jeremy is putting more than $100,000 of his own money into it, all you have to do is click here now.
The article 3 Keys to This Surging Biotech's Star-Studded Year originally appeared on Fool.com.
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.